2024-10-07 - Analysis Report
## Regeneron Pharmaceuticals Inc (REGN) Stock Analysis

**Company Overview:** Regeneron Pharmaceuticals Inc is a biotechnology company focused on developing and commercializing life-transforming medicines for serious diseases.

**Performance Analysis:**

1. **Performance vs. S&P 500 (VOO):** 
   * **Cumulative Return:**  REGN (92.97%) has underperformed VOO (133.14%) by **-40.17%**.
   * **Relative Divergence:** Currently at -40.17%, which represents 35.43% of the historical range (-75.36% to 32.46%). This signifies that REGN's performance has been relatively weaker compared to the S&P 500.

2. **Recent Price Movements:**
   * **Closing Price:** $1012.82
   * **5-day Moving Average:** $1033.17 (Slight downtrend)
   * **20-day Moving Average:** $1094.86 (Moderate downtrend)
   * **60-day Moving Average:** $1115.43 (Strong downtrend)

3. **Technical Indicators:**
   * **RSI:** 22.12 (Oversold territory, potential for rebound)
   * **PPO:** -0.9 (Sell signal, indicating bearish momentum)
   * **Delta_Previous_Relative_Divergence:** -27.97 (Short-term downtrend)
   * **Expected Return:** 0.0% (5-year projected return based on current market conditions, relative to S&P 500).

4. **Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-01 | 13.25 | $3.55 B |  
| 2024-05-02 | 6.7 | $3.15 B | 
| 2023-11-02 | 9.48 | $3.36 B | 
| 2023-08-03 | 9.05 | $3.16 B |
| 2024-08-01 | 9.05 | $3.16 B | 

**Most Recent Earnings (2024-08-01):** The company surpassed analyst expectations, with EPS of 13.25 exceeding forecasts. Revenue of $3.55 billion was also higher than expected, indicating robust growth.

5. **News and Recent Issues:**

* **Recent Market Outlook:**  REGN has faced challenges in the recent market, with share price experiencing a significant dip. Analyst sentiment remains mixed, with some expecting a rebound driven by strong product pipelines while others anticipate continued headwinds.
* **Analyst Opinions:**  The stock has a wide range of analyst ratings, from buy to sell, reflecting the uncertainty surrounding its future performance. Key factors impacting sentiment include the performance of key products, regulatory approvals, and competition in the market.
* **Performance Highlights:** REGN's performance has been affected by a variety of factors, including the ongoing COVID-19 pandemic, competition in the biopharmaceutical market, and fluctuations in the broader stock market.

**Overall Analysis:**

REGN's stock is currently facing several challenges, including weaker performance relative to the S&P 500, bearish technical indicators, and market uncertainty. However, strong recent earnings results, a robust product pipeline, and potential for long-term growth could support a rebound. Investors should closely monitor the company's upcoming earnings releases, regulatory updates, and market developments for insights into future performance. The current oversold conditions suggest a potential for a short-term rebound, but long-term prospects remain uncertain.

**Disclaimer:** This analysis is for informational purposes only and should not be considered investment advice. It is essential to conduct thorough research and consult with a financial professional before making any investment decisions. 
